Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers
NCT07531316Phase 1Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VVZ-2471 in substance use disorder (SUD) (3 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Adverse Events at 14 days. Started Aug 2026; status: recruiting.
02
Drugs
VVZ-2471
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT07531316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531316.